This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



galcanezumab (Emgality®)


Reference No. 3788

Publication date:
14/05/2019


Appraisal information

galcanezumab (Emgality®) 120 mg solution for injection


Company: Eli Lilly & Co Ltd
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 09/05/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, galcanezumab (Emgality®) cannot be endorsed for use within NHS Wales for the prophylaxis of migraine in adults who have at least four migraine days per month
Statement of Advice (SOA)
Download